Manila Times Business
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers Parallel survey of payers shows strong support for Annamycin filling a significant unmet need HOUSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), today announced results from an independent market landscape assessment evaluating Annamycin in relaps
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
BC-Driven Breakthrough: TCL Solar's Value Leap from Wafer Leadership to Tier 1 Module Supplier
Just now
Making Sustainability Count on World Environment Day: How Beko Focuses on Lowering Water and Energy Consumption from Factories to Homes
Just now
PropMarket Launches as the First Prop Firm Built for Prediction Markets
Just now
Announcement from Eimskip
Just now